Glutamine depletion strongly inhibits the replication of Rauscher murine leukaemia retrovirus (RLV) in vitro. Pseudomonas 7.4 glutaminase-asparaginase (PGA), capable of depleting glutamine and asparagine for prolonged periods, was used to determine the therapeutic effectiveness ofglutamine depletion in mice infected with RLV or Friend virus. During PGA treatment of viraemic animals, serum reverse transcriptase activity fell to control levels and infected animals did not develop splenomegaly. The therapeutic results obtained with PGA compared favourably with those of azidothymidine given intraperitoneally at 30 mg/kg/day. Western blots performed on splenic tissue from control and treated animals indicated that glutamine depletion prevented readthrough of an amber codon at the gag-poljunction, stopping translation of viral mRNA at that point. Treatment of RLVinfected animals with PGA resulted in nearly a 200% increase in mean survival time even when therapy was initiated late in the course of the disease. To our knowledge, this is the first demonstration that a nutrient required for viral replication can be enzymically depleted in vivo to inhibit viral replication.
Introduction
It is well established that the Retroviridae infect a host cell through receptor recognition mechanisms, insert their genomic RNA, then make DNA copies which integrate throughout the genome (Varmus, 1989) . After variable periods of latency this proviral DNA initiates transcription, ultimately resulting in the production of infectious virions and disease progression. The correct processing of the gag, pol and env genes of integrated retroviral DNA is essential for infectivity (Yoshinaka et al., 1985) and there is a correlation between progressive retroviral disease and the number of infectious particles (Falk et al., 1987) . Gloger et al. have reported that glutamine was required for the synthesis of the Moloney murine leukaemia virus (Mo-MuLV) in vitro, and that the inhibition of virus replication observed when glutamine is removed from the tissue culture medium is not secondary to general inhibition of protein synthesis or to cell cycle arrest (Gloger et al., 1985; Gloger & Panet, 1986) . We wished to determine whether depletion of glutamine in vivo would have an effect on viraemia and on subsequent disease. The Rauscher murine leukaemia virus (RLV) and Friend virus (FV) diseases were chosen as primary models because of their induction of a rapidly fatal erythroleukaemia in virtually 100% of susceptible t Present address: Carcinogenesis Laboratory, Department of Microbiology and Department of Biochemistry Michigan State University, East Lansing, Michigan 48824, U.S.A. mice (Rauscher, 1962; Marks & Rifkind, 1978) and their use as a model for screening drugs with potential anti-human immunodeficiency virus (HIV) activity (Ruprecht et al., 1986) . We have found that RLV requires glutamine for replication in vitro . In the present study mice infected with RLV or FV were treated with crystalline Pseudomonas 7A glutaminase-asparaginase (PGA) (Roberts, 1976) . This enzyme, which lowers serum and tissue glutamine and asparagine levels for prolonged periods, has been used successfully to treat a variety of murine and human tumours (Roberts et al., 1979; Rosenfeld & Roberts, 1981 ; . Treatment of retrovirus-infected mice with PGA resulted in substantial reduction in serum reverse transcriptase activity (RTA), reduction in spleen XC titre and in improved long-term survival benefits. Whether this unique approach can be applied to other pathogenic viruses will depend upon the identification of nutritional requirements for viral propagation and the development of bioactive enzymes to deplete these nutrients in the vicinity of infected cells.
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J. Roberts and W. G. McGregor 1988) . Persistently infected cells were allowed to attach, then pretreated for 12 h in medium deficient in a specific amino acid and containing 8 ~ dialysed calf serum. Media deficient in specific amino acids were prepared from a Select-Amine/EMEM kit (Gibco). At time 0 the cells were counted and the media replaced into parallel flasks for an additional 12 to 24 h. RTA and XC assays in SC-1 cells (Rowe et aL, 1970) were performed at 6 h intervals.
Focus formation assay. The bioactivity of viral stocks, harvested from cell culture medium (RVB3) or spleen extracts of FV-infected mice, was determined by injecting 250 ~tl of serially diluted stock intravenously on day 0 into BALB/cBy-J mice using four mice per dilution. On day 9, two mice for each dilution were sacrificed, the spleens fixed in Bouin's solution and the foci counted. The remaining mice were sacrificed on day 20 for determination of spleen weights. Generally, dilutions of 1 : 100 resulted in 15 to 20 foci per spleen.
Reverse transcriptase assay. RTA was determined by mixing 50 [11 of serum with 35 Ixl of buffer containing (final concentrations) 50 mMTris-HCl, 1 mM-DTT, 0.5 m~-MnCl 2, 50 mM-KC1 and 0.05~ Triton X-100 pH 8.2. The solutions were kept on ice while 5 ~1 of a 1 mg/ml solution of poly(A)-oligo(dT)12_ls template-primer (Pharmacia) was added per tube. The reactions were started by the addition of 10 p.Ci of [3H]thymidine triphosphate (1CN) and continued for 1 h at 37 °C. The products were analysed by spotting 80 ~tl of the reaction mixture onto Whatman DE-81 ion-exchange filter paper. Each filter paper was washed five times with 5 ml of 5 ~ Na2HPO4, once wit h 5 ml of doubledistilled H2 O and finally with 1 ml of 95~ ethanol. The papers were dried and counted in Scintiverse in a Beckman LS-150 scintillation counter. RTA was expressed as d.p.m, bound to the ion exchange paper after subtraction of background.
Glutaminase and asparaginase assays. PGA was purified to a homogeneous state as previously described (Roberts, 1976) . Glutaminase and asparaginase activities were determined by direct nesslerization of the NH3 produced in their reactions. For a routine assay 0.1 ml of enzyme solution [diluted with cold 0-1 M-sodium phosphate buffer pH 7.2 containing 5 mg/ml of crystalline bovine serum albumin (BSA)] was added to 0.4 ml of Tris-HCl buffer (0.1 M pH 7.5), which contained 25 mM-glutamine or -asparagine. Incubations were conducted for 15 rain at 37 °C. The reaction was stopped by the addition of 0.5 ml of 0.5 t,l-H2SO~. The precipitated protein was removed by centrifugation and 0.2 ml of supernatant was diluted with 3-8 ml of water. Nessler's reagent (0.5 ml) was added and the absorbance at 400 nm was measured within 1 to 3 rain. Enzyme and substrate blanks were included in all assays and a standard curve was prepared with ammonium sulphate. One international unit (IU) of activity is defined as that amount of enzyme which catalyses the formation of 1 ~tmol of ammonia/rain under the conditions of the assay.
Short-term animal studies. Female BALB/cBy-J mice (4 to 6 weeks old) were injected intravenously (i.v.) with 1-5 x 103 p.f.u, of RLV RVB3 strain (Table 1) . Control mice received saline. Viral inoculations were made on day 0 and 4 h later one of six protocols was started. Groups 1 and 2 received saline three times weekly. Groups 3 and 4 received 200 IU/kg of PGA intraperitoneally (i.p.) three times weekly. Groups 5 and 6 received 6 mg/kg of the glutamine analogue 6-diazo-5-oxo-L-norleucine (DON) i.p. 6 h after PGA. Groups 7 and 8 received 6 mg/kg of DON i.p. as a single agent. Group 9 received 10 mg/kg of azidothymidine (AZT) (a gift from Dr R. Schinazi, VA Medical Center, Atlanta, Ga., U.S.A.) and groups 10 and 11 received 30 mg/kg of AZT all given i.p. daily. Groups 12 and 13 received 200 IU/kg of Escherichia coli asparaginase (Merck & Company) daily. On day 21, at least 24 h after the last dose of any drug, the animals were sacrificed by cervical dislocation after weighing and obtaining blood. The percentage inhibition of spleen weight was calculated by the formula
, where x is the spleen weight of an infected, treated animal, y is the spleen weight of an uninfected treated animal, e that of an infected untreated animal and n that of a normal age-and sexmatched BALB/c mouse. The plasma XC titration was performed by diluting plasma 1:10 in phosphate-buffered saline and performing dilutions from 10 -2 to 10 -5 , thereby diluting out any residual enzyme or drug. The reverse transcriptase assay was performed on undiluted plasma which may have contained residual enzyme or drug. We have determined that glutaminase, asparaginase and DON do not interfere with the reverse transcriptase assay. The short half-life of AZT would preclude inhibitory plasma concentrations of this drug 24 h after a dose.
Long-term animal studies. Female BALB/cBy-J mice (4 to 6 weeks old) were injected i.v. with 1.5 x 103 p.f.u, ofFV (pol_ycythaemic strain) or the RVB3 strain of RLV (Fig. 1 , Table 2 ). Treatment was started either 4 h (early) or 14 days (late) after viral inoculation. 200 IU/kg of PGA and 6 mg/kg or DON were administered i.p. three times weekly. In the PGA/DON group, DON was given 5 to 6 h after the enzyme. The animals were followed for signs of splenomegaly and were bled weekly for measurement of plasma RTA and glutaminase where appropriate. Treatments were continued until the animals died.
The animal care program and facilities at the University of South Carolina are fully accredited by AAALAC and are in compliance with the Guide for the Care and Use of Laboratory Animalsl These studies also adhered to the Public Health Service 'Policy on Humane Care and Use of Laboratory Animals'.
Western blots. Analysis of viral polyproteins in the spleens of infected animals was performed using an immunoblotting procedure. Splenocytes were sonicated in lysis buffer (0-05 M-Tris-HC1 pH 7-2, 0.5~ NP40, 0.5~ sodium deoxycholate, 0.1 M-NaC1, 1 m~-EDTA and 1 mM-PMSF) and centrifuged at 15000g for 30rain at 4°C. The supernatants were assayed for protein by the Coomassie blue method.
125i_labelled MT standards or 50 ~tg of each protein sample were applied to a 20 cm 5 to 10% gradient polyacrylamide gel containing 0.4% SDS. The samples were electrophoresed overnight using an electrode buffer of 25 mM-Tris-HC1 pH 8-3, 10 mM-glycine and 0.1% SDS. The proteins were electrophoretically transferred to nitrocellulose (Bio-Rad) using 250 V for 4 to 6 h. The nitrocellulose was 'blocked' with 25 mM-Tris-HC1 pH 8-3 containing 1 ~ BSA, then washed extensively with 25 mMTris-HCl pH 8.3. The blots were exposed for 12 h to a 1:20 dilution of polyclonal anti-RLV antiserum which recognizes gag antigens (Electro-Nucleonics). The blots were washed with 25 mM-Tris-HC1 pH 8.3, then probed with l~51-1abelled Protein A. Excess l zSI-labelled Protein A was removed by washing with 25 mM-Tris-HC1 pH 8.3 and autoradiography was performed for 18 h at -70 °C using Kodak X-Omat film.
Results and discussion
Effect of amino acid depletion on RLV strain RVB3 production in vitro After attachment, SC-1 cells persistently infected with RVB3 virus were placed in media depleted of one of the following amino acids: glutamine, leucine, arginine, tryptophan, phenylalanine/tyrosine, methionine, histidine or cysteine. Viable cell counts, RTA and XC titres were determined every 6 to 10 h for 48 h. When corrected for viable cell counts, 6 to 8 h of glutamine depletion consistently reduced the medium RTA 300-fold and the Retroviral disease inhibition by glutaminase 301 XC titre 500-fold. By 18 h, medium RTA was not detectable and the XC titre was reduced approximately 1000-fold. By contrast, there was slight or no effect of depletion of the other amino acids; cysteine could not be evaluated since its depletion caused the SC-1 cells to become non-viable within 12 h. The observed effects did not appear to be secondary to toxic effects on the SC-1 cells since the parameters of viral synthesis dropped dramatically within 6 h, when viable cell counts in the glutamine-depleted medium were only slightly less than those of the control. The inhibition of viral replication did not appear to be secondary to general inhibition of protein synthesis since depletion of essential amino acids such as leucine and tryptophan had minimal effects on viral titre or RTA in the medium. It is also unlikely that glutamine depletion inhibited virus replication by arresting the cell cycle, since the cells were dividing (although at a reduced rate) through at least 24 h of glutamine deprivation. In addition, cell cycle arrest with sodium butyrate has been reported to have no effect on Mo-MuLV virus production (Ginger et al., 1985) . In preliminary experiments, we have determined that glutamine is also required for the synthesis of Mo-MuLV and SL3-3 and LP-BM5 (Hartley et al., 1989 ) murine retroviruses.
Effect of glutamine depletion on RLV-or FV-induced disease
Having confirmed that glutamine was required for RLV replication, it was of interest to determine whether therapy with PGA would have survival benefits for the mice. Following i.v. injection of BALB/c mice with RLV RVB3 strain, red cell precursors were infected leading to splenic colony formation in 8 days, massive splenomegaly due to erythroblast infiltration in 21 days and death within 4 to 5 weeks (Boiron et al., 1965) . There was a linear correlation between the spleen weights on day 20 and viral titre (Chirigos, 1964) . Table 1 shows the effect of various treatment regimens started 4 h post-infection (p.i.) on splenomegaly, mean plasma XC titre and mean plasma RTA. PGA alone or in combination with the glutamine antimetabolite DON resulted in virtually complete inhibition of splenomegaly, plasma XC titre and plasma RTA. When DON was used as a single agent starting immediately after infection there was some ant±viral effect, with 56~ inhibition of spleen weight and roughly corresponding decreases in plasma XC titre and plasma RTA. Since PGA deamidates L-asparagine at a rate approximately one-half that of L-glutamine, the effect of E. col± asparaginase was tested. The E. col± asparaginase, which also has some glutaminase activity, produced significant inhibition of splenomegaly; however, there was only about a 10-fold decrease in RTA and XC titres. In contrast, treatment with PGA resulted in a 1000-fold inhibition of viraemia. It is likely that the partial inhibition of viral production by E. col± asparaginase is due to glutamine deprivation, since experiments showed that serum glutamine as well as serum asparagine concentrations were lowered by this enzyme. This hypothesis is further supported by the observation that asparagine depletion did not inhibit mouse retroviral production in vitro. The results for PGA and PGA/DON therapy compared favourably with AZT (30 mg/kg/day) given i.p. ; all three regimens effectively inhibited viral replication when treatment was started within 4 h p.i. Treatments at the doses indicated were well tolerated by the animals.
When treatment with PGA or PGA/DON was initiated 14 days p.i., when the animals were late in the course of the disease, there was a significant improvement in splenomegaly and 95~ reduction in plasma RTA after 2 weeks of therapy (Fig. 1) . No p.f.u, were detectable in the plasma of PGA-or PGA/DON-treated animals. In contrast, DON used as a single agent reduced splenomegaly 36~ and plasma RTA 40~, and the plasma XC titre of the DON-treated animals was as high as that of the untreated controls at the time of sacrifice (Fig. 1) . Table 2 illustrates the long-term survival benefits when PGA, DON or PGA/DON regimens were started immediately (4 h) after viral inoculation or late in the course of the disease (14 days p.i.). When PGA alone was administered 4 h p.i. the animals remained clinically well until circulating glutaminase became inactivated possibly due to the development of neutralizing antibodies to the enzyme. The inactivation of PGA was subject to wide individual variation, but generally occurred after about 2 weeks of therapy. When individual mice were bled weekly for serum PGA and RTA, it was found that a disappearance of plasma PGA activity preceded a rise in RTA levels and gradual development of splenomegaly. Animals generally died within 14 to 21 days after plasma glutamine levels returned to normal.
Administration of DON, a glutamine analogue with known anti-neoplastic activity (Rosenfeld & Roberts, 1981) improved survival as well as PGA when it was administered early in the course of the disease, but did not significantly improve survival when given late in the disease. It is possible that the moderate antiviral effect of DON (Table 1 , group 7) together with its antineoplastic activity could stabilize the disease in its earliest stages, but the much stronger antiviral activity of PGA was required to improve survival in advanced disease.
Coadministration of DON with PGA prolonged animal survival compared with either agent alone. The combination has been shown to possess antineoplastic activity ) and the treatment may improve survival to some extent by inhibiting the growth of transformed erythroblasts. However, glutaminase has been found to have little activity against RLV erythroleukaemia cells in vivo (Holcenberg, 1981) , and it is likely that the primary mode of activity of pGA is through inhibition of viral synthesis. We have found that coadministration of DON with glutaminase greatly prolongs the circulating activity of the enzyme (Roberts & Rosenfeld, 1980) . We believe that the greatest benefit of DON in these studies was to prolong the circulating activity of PGA, thereby extending the therapeutically useful lifespan of the enzyme. When treatment with PGA was initiated 2 weeks p.i. the disease was stabilized and viral production was essentially halted. Animals improved until circulating glutaminase disappeared, at which time the disease process resumed.
Similar results were obtained when mice were injected with FV and treated with PGA, DON or PGA/DON. Long-term treatment with PGA begun 4 h p.i. resulted in a 229~o increase in mean survival time (MST) and PGA/DON treatments resulted in a 262~ increase in MST. The MST of animals treated with DON alone was increased 48~ relative to that of controls. Two of 10 animals infected with FV and treated with PGA alone did not inactivate the enzyme; consequently, these mice were treated for 15 weeks with PGA. When the animals were sacrificed on day 105, their spleen weights were only slightly above normal, and there were no spleen foci characteristic of Friend disease.
The course of therapy and the observed MSTs were limited by the tendency of the mice eventually to Retroviral disease inhibition by glutaminase 303 inactivate the PGA. We are working on strategies to increase the duration of the enzyme therapy by purifying the protein from different organisms to produce antigenically distinct enzymes for sequential administration and by chemical modification of the enzyme to reduce its antigenicity. Development of anti-glutaminase antibodies may not be a problem in humans, since initial studies have indicated that even after prolonged treatment with bacterial glutaminase-asparaginase in cancer patients there was no evidence of formation of neutralizing antibodies or allergic reactions (Mita et al., 1980) . The mechanism of glutaminase suppression of splenomegaly and viraemia can best be explained by interference with viral mRNA translation. The replicationcompetent type C murine retroviruses contain an amber termination codon at the junction of the gag and pol genes, and in vitro studies with Mo-MuLV have shown that glutamine is required for readthrough (Yoshinaka et al., 1985) . This effect has been shown to be specific for glutamine (Gloger & Panet, 1986) and is not secondary to cell cycle arrest or general inhibition of protein synthesis (Gloger et al., 1985) . We have also reported that depletion of essential amino acids such as leucine or tryptophan had little or no effect on the XC titre of the tissue culture medium of SC-1 cells infected with RLV, whereas glutamine depletion reduced the XC titre over 1000-fold . Fig. 2 illustrates that glutamine depletion by PGA in vivo has a similar effect on RLV translation. A Western blot of spleen extracts from infected animals treated with saline (lane 2), PGA (lane 3), PGA/DON (lane 4) or DON (lane 5) was performed using polyclonal anti-RLV antiserum as a probe. The readthrough gene product Pr1809ag-pol as well as the gag antigen Pr659ag and the proteolytic product Pr309a9 were present in the spleens of infected controls and in infected animals treated with DON. Other gag proteins, e.g. Prl0, Prl2 or Prl5, were not seen on this blot possibly because these small proteins ran very close to the dye front on the gradient gel. It is also possible that the polyclonal anti-RLV antiserum did not recognize these epitopes, since other investigators using that antiserum were unable to immunoprecipitate Pr659a9 cleavage products other than Pr30 (Gloger & Panet, 1986) . While the qualitative nature of the immunoblot does not allow comparison of the relative concentrations of Prl80, Pr65 and Pr30, it is remarkable that PGA abolished Pr65 readthrough to such an extent that neither the readthrough product nor the proteolysis product could be detected on the deliberately overexposed film shown in Fig. 2 . However, Pr65ga9 was present, indicating that the virus was integrated into the genome of target cells of PGA-treated animals, but viral mRNA could not be fully translated when the glutamine concentration was enzymically reduced. Participation of a cellular amber suppressor tRNAoln appears to be required for gag-pol readthrough (Yoshinaka et al., 1987; Kuchino et al., 1988; Feng et al., 1989) and it has been suggested that some cis-acting element in the viral mRNA may be important for amber suppression (Panganiban, 1988) . Whatever the mechanism, successful production of infectious virions requires a ratio of 20 gag proteins to one fusion protein (Varmus, 1989) . Glutamine depletion appears to alter this ratio, possibly by lowering the concentration of aminoacylated amber suppressor tRNA g~" relative to the major tRNAg~n. In these circumstances, viral mRNA translation would Stop at the gag-pol junction, the fusion protein would fall below the critical level and the production of infectious virions would cease. Testing this hypothesis awaits data on the kinetics of aminoacylation of the amber suppressor tRNA as well as the major tRNA gIn. Treatment of animals with bacterial glutaminase-asparaginase has been shown to result in four-to 10-fold reductions in tissue glutamine concentrations (Holcenberg, 1981; J. Roberts, unpublished results) and this reduction may be sufficient to remove the suppression of the stop codon following the gag reading frame. Human pathogenic retroviruses do not have a stop codon at the gag-pol junction, but instead have significant overlap of the gag and pol open reading frames (Jacks et al., 1988) . Regulation of the synthesis of the gag-pol fusion protein is due instead to a ribosomal frameshift mechanism (VarmUs, 1989) . Nevertheless, HT9 cells infected with HIV type 1 (HIV-1) have been 304
J. Roberts and W. G. McGregor found to have a high level of the amber suppressor tRNAg~n, and reduction in the level of this tRNA is associated with a reduction in the synthesis of viral protease (MOiler et al., 1988) . It will be of interest to determine whether depletion of exogenous glutamine interferes with the processing of HIV-1 or human T cell leukaemia virus type-1. To our knowledge this is the first demonstration that a specific viral nutritional requirement can be exploited in vivo to provide therapeutic benefit to the infected animal. Murine leukaemia viruses have been shown to be sensitive to a reduction in the extracellular (and presumably intracellular) glutamine concentration which disrupts viral mRNA translation. The inability of the virus to replicate resulted in clinical improvement and an increase in survival. Although enzyme treatment had relatively low toxicity, it may be possible to improve the therapeutic index of the enzyme by chemically linking it to a monoclonal antibody directed against viral antigens expressed on the surface of infected cells. Chemical modification of enzymes with polyethylene glycol (PEG) has been shown to reduce the antigenicity of E. coli asparaginase (Kurtzberg et al., 1988) and adenosine deaminase (Hershfield et al., 1987) . Preliminary results have shown that PEG treatment of PGA increases the enzyme half-life several fold (unpublished observations), and it is possible that treatment with the modified enzyme could further improve survival. If unique nutritional requirements for the replication of other pathogenic viruses can be identified it may be possible to develop specific catabolic enzymes for use as therapeutic agents.
